Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids.

Abstract:

BACKGROUND:We have observed an increase in hepatotoxicity (DILI) reporting related to the use of anabolic androgenic steroids (AAS) for bodybuilding. AIM:To characterise phenotype presentation, outcome and severity of AAS DILI. METHODS:Data on 25 cases of AAS DILI reported to the Spanish (20) and Latin-American (5) DILI Registries were collated and compared with previously published cases. RESULTS:AAS DILI increased from representing less than 1% of the total cases in the Spanish DILI Registry in the period 2001-2009 to 8% in 2010-2013. Young men (mean age 32 years), requiring hospitalisation, hepatocellular injury and jaundice were predominating features among the AAS cases. AAS DILI caused significantly higher bilirubin values independent of type of damage when compared to other drug classes (P = 0.001). Furthermore, the cholestatic AAS cases presented significantly higher mean peak bilirubin (P = 0.029) and serum creatinine values (P = 0.0002), compared to the hepatocellular cases. In a logistic regression model, the interaction between peak bilirubin values and cholestatic damage was associated with the development of AAS-induced acute kidney impairment (AKI) [OR 1.26 (95% CI: 1.035-1.526); P = 0.021], with 21.5 ×ULN being the best bilirubin cut-off point for predicting AKI risk (AUCROC 0.92). No fatalities occurred. CONCLUSIONS:Illicit recreational AAS use is a growing cause of reported DILI that can lead to severe hepatic and renal injury. AAS DILI is associated with a distinct phenotype, characterised by considerable bilirubin elevations independent of type of damage. Although hepatocellular injury predominates, acute kidney injury develops in cholestatic cases with pronounced jaundice.

journal_name

Aliment Pharmacol Ther

authors

Robles-Diaz M,Gonzalez-Jimenez A,Medina-Caliz I,Stephens C,García-Cortes M,García-Muñoz B,Ortega-Alonso A,Blanco-Reina E,Gonzalez-Grande R,Jimenez-Perez M,Rendón P,Navarro JM,Gines P,Prieto M,Garcia-Eliz M,Bessone F,Brahm

doi

10.1111/apt.13023

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

116-25

issue

1

eissn

0269-2813

issn

1365-2036

journal_volume

41

pub_type

杂志文章
  • Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

    abstract:BACKGROUND:HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. AIMS:To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in patients with chronic hepatitis B (CHB) infection METHODS: Treatment-naïve subjects with non-cirrhot...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16196

    authors: Zhang H,Hu Y,Wu M,Liu J,Zhu X,Li X,Chen H,Li C,Liu C,Niu J,Ding Y

    更新日期:2021-01-01 00:00:00

  • Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.

    abstract:BACKGROUND:Although incrimination of the intestinal microbiota in the pathogenesis of IBD is widely accepted, few data are available about the role of specific bacteria. Potentially, Faecalibacterium prausnitzii, bacteria with anti-inflammatory properties, might be deficient in ulcerative colitis (UC). AIM:To quantify...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12365

    authors: Varela E,Manichanh C,Gallart M,Torrejón A,Borruel N,Casellas F,Guarner F,Antolin M

    更新日期:2013-07-01 00:00:00

  • The treatment of irritable bowel syndrome.

    abstract::The efforts of clinical researchers, lay organizations and pharmaceutical companies have increased the public profile of irritable bowel syndrome and made it a respectable diagnosis. Diagnostic symptom criteria encourage a firm clinical diagnosis, which is the foundation of a logical management strategy. This begins w...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01312.x

    authors: Thompson WG

    更新日期:2002-08-01 00:00:00

  • The impact of hepatitis C burden: an evidence-based approach.

    abstract:BACKGROUND:Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertai...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12625

    authors: Younossi ZM,Kanwal F,Saab S,Brown KA,El-Serag HB,Kim WR,Ahmed A,Kugelmas M,Gordon SC

    更新日期:2014-03-01 00:00:00

  • Review Article: pain versus discomfort--is differentiation clinically useful?

    abstract::Functional dyspepsia is highly variable in its clinical presentation and multifactorial in its underlying causes. Since many of the symptoms included in the definition of dyspepsia are intuitively suggestive of different pathogenic mechanisms, it has been proposed that patients with functional dyspepsia be divided int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2001.00906.x

    authors: Stanghellini V

    更新日期:2001-02-01 00:00:00

  • Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection.

    abstract::A long-term cure is now possible in more than 30% of selected patients with Zollinger-Ellison syndrome who undergo gastrinoma resection. The need, however, for continued gastric acid antisecretory therapy in these patients remains controversial. The current study was designed to determine whether post-operative antise...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1993.tb00095.x

    authors: Metz DC,Benya RV,Fishbeyn VA,Pisegna JR,Orbuch M,Strader DB,Norton JA,Jensen RT

    更新日期:1993-06-01 00:00:00

  • Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial.

    abstract:BACKGROUND:Misoprostol is known to be effective in stimulating intestinal transit both in healthy individuals and in patients with chronic constipation when evaluated in short-term trials. The aim of this study was to determine the utility of misoprostol in the long-term management of patients with chronic refractory c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1997.00237.x

    authors: Roarty TP,Weber F,Soykan I,McCallum RW

    更新日期:1997-12-01 00:00:00

  • Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children.

    abstract:BACKGROUND:There has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases. AIM:To review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12699

    authors: Sha S,Liang J,Chen M,Xu B,Liang C,Wei N,Wu K

    更新日期:2014-05-01 00:00:00

  • A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.

    abstract:BACKGROUND:Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule. AIM:To compare the safety and efficacy of sul- fasalazine, 3 g, wi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2002.01151.x

    authors: Mansfield JC,Giaffer MH,Cann PA,McKenna D,Thornton PC,Holdsworth CD

    更新日期:2002-01-01 00:00:00

  • The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.

    abstract:BACKGROUND:Studies have shown that past alcohol consumption reduces response rates in patients with chronic hepatitis C treated with interferon monotherapy. AIM:To clarify the importance of alcohol consumption on response rates in patients undergoing treatment with pegylated interferon and ribavirin. METHODS:In a sin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02631.x

    authors: Chang A,Skole K,Gautam M,Schmutz J,Black M,Thomas R,Horwitz B,Friedenberg FK

    更新日期:2005-10-15 00:00:00

  • Time trends in peptic ulcer, erosive reflux oesophagitis, gastric and oesophageal cancers in a multiracial Asian population.

    abstract:BACKGROUND:Dramatic changes in the prevalence and pattern of gastrointestinal disease has taken place in Asia in recent years. AIM:To compare the prevalence of duodenal (DU) and gastric ulcers (GU), erosive oesophagitis (EO), gastric cancer (GCA) and oesophageal cancer (OCA) and Helicobacter pylori infection over a 10...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.03930.x

    authors: Goh KL,Wong HT,Lim CH,Rosaida MS

    更新日期:2009-04-01 00:00:00

  • Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

    abstract:BACKGROUND:Recent evidence found probiotics could inhibit Helicobacter pylori colonization from both in vitro and in vivo studies. AIM:To systematically evaluate whether adding probiotics to anti-H. pylori regimens could improve eradication rates and reduce side effects during anti-H. pylori treatment. METHODS:Eligib...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2006.03179.x

    authors: Tong JL,Ran ZH,Shen J,Zhang CX,Xiao SD

    更新日期:2007-01-15 00:00:00

  • Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy.

    abstract:BACKGROUND:Spontaneous portosystemic shunt (SPSS) is a frequent cause of recurrent hepatic encephalopathy (HE) in patients with cirrhosis. AIM:To assess the effectiveness and optimal candidate selection for embolisation of SPSS, for the treatment of recurrent HE in patients with cirrhosis. METHODS:This retrospective ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12771

    authors: An J,Kim KW,Han S,Lee J,Lim YS

    更新日期:2014-06-01 00:00:00

  • Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

    abstract:BACKGROUND:The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. AIM:To evaluate the effecti...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14479

    authors: Bär F,Kühbacher T,Dietrich NA,Krause T,Stallmach A,Teich N,Schreiber S,Walldorf J,Schmelz R,Büning C,Fellermann K,Büning J,Helwig U,German IBD Study Group.

    更新日期:2018-03-01 00:00:00

  • Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause.

    abstract:BACKGROUND:As there is considerable overlap between the fasting serum gastrin concentrations found in Zollinger-Ellison syndrome and various common conditions such as Helicobacter pylori infection and acid suppressing medication use, establishing the cause of hypergastrinaemia in individual cases can sometimes be diffi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.03976.x

    authors: Murugesan SV,Varro A,Pritchard DM

    更新日期:2009-05-15 00:00:00

  • Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2004.02294.x

    authors: Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

    更新日期:2005-01-01 00:00:00

  • Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

    abstract::Alginate-based raft-forming formulations have been marketed word-wide for over 30 years under various brand names, including Gaviscon. They are used for the symptomatic treatment of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of g...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00759.x

    authors: Mandel KG,Daggy BP,Brodie DA,Jacoby HI

    更新日期:2000-06-01 00:00:00

  • Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children.

    abstract:BACKGROUND:Recent genome-wide association studies based on adult and paediatric populations have implicated >30 genes/loci as susceptibility loci for Crohn's disease (CD). AIMS:To investigate whether reported genes/loci were also associated with CD in Canadian children. DESIGN AND METHODS:A case-control design was im...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2010.04294.x

    authors: Amre DK,Mack DR,Morgan K,Israel D,Deslandres C,Seidman EG,Lambrette P,Costea I,Krupoves A,Fegury H,Dong J,Grimard G,Levy E

    更新日期:2010-06-01 00:00:00

  • Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.

    abstract:BACKGROUND:Fibroblast growth factors play an important role in (patho)physiological processes such as wound healing and tissue repair. We previously showed that basic fibroblast growth factor is actively involved in inflammatory bowel disease processes. In the present retrospective study, we assessed whether serum basi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.02126.x

    authors: Gao Q,Hogezand RA,Lamers CB,Verspaget HW

    更新日期:2004-09-01 00:00:00

  • Oral or intravenous erythromycin has no effect on human distal colonic motility.

    abstract::Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors. Its effect on pressure activity of the human colon has not been investigated. Eight healthy volunteers were studied on 2 occasions and given intravenous or ora...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1992.tb00573.x

    authors: Jameson JS,Rogers J,Misiewicz JJ,Raimundo AH,Henry MM

    更新日期:1992-10-01 00:00:00

  • Review article: the treatment of hepatitis C virus recurrence after liver transplantation.

    abstract:BACKGROUND:Recurrent hepatitis C represents a major challenge for the liver transplant community. Given the potentially significant impact that hepatitis C recurrence has on graft and patient survival, several treatment strategies have been utilized to prevent/slow the progression to hepatitis C-related graft failure. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03364.x

    authors: Arjal RR,Burton JR Jr,Villamil F,Rosen HR

    更新日期:2007-07-15 00:00:00

  • Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study.

    abstract:BACKGROUND:Germinated barley foodstuff (GBF) has been shown to attenuate intestinal injury in animal models, largely by increasing luminal short-chain fatty acid production. AIM:To investigate the safety and efficacy of GBF in the treatment of ulcerative colitis (UC). METHODS:Ten patients with active UC received 30 g...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1998.00432.x

    authors: Mitsuyama K,Saiki T,Kanauchi O,Iwanaga T,Tomiyasu N,Nishiyama T,Tateishi H,Shirachi A,Ide M,Suzuki A,Noguchi K,Ikeda H,Toyonaga A,Sata M

    更新日期:1998-12-01 00:00:00

  • Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited.

    abstract:BACKGROUND:Restriction of dietary FODMAP intake can alleviate symptoms in patients with irritable bowel syndrome. Because many FODMAPs have prebiotic actions, there is concern that their dietary restriction leads to dysbiosis with health consequences, and their intake is being encouraged by addition to foods and via su...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15818

    authors: Gibson PR,Halmos EP,Muir JG

    更新日期:2020-07-01 00:00:00

  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract:BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2007.03583.x

    authors: Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期:2008-02-15 00:00:00

  • Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.

    abstract:BACKGROUND:Patients with chronic hepatitis B (CHB) need long-term antiviral treatment with nucleos(t)ide analogues (NA). Animal studies suggest that some NA may increase cancer risk, but human data are lacking. AIM:To investigate cancer risks in patients with or without NA treatment. METHODS:We conducted a territory-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14015

    authors: Wong GL,Tse YK,Yip TC,Chan HL,Tsoi KK,Wong VW

    更新日期:2017-05-01 00:00:00

  • Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study.

    abstract:BACKGROUND:Non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal side effects. Faecal calprotectin assay represents a simple and practical method for diagnosis of NSAID enteropathy. Intestinal micro-organisms are necessary for the development of NSAID-induced small bowel lesions and hence it...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2010.04324.x

    authors: Montalto M,Gallo A,Curigliano V,D'Onofrio F,Santoro L,Covino M,Dalvai S,Gasbarrini A,Gasbarrini G

    更新日期:2010-07-01 00:00:00

  • Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto.

    abstract:BACKGROUND:Surgical resection of Crohn's disease is followed by early recurrence in a high percentage of patients. Mesalazine has been shown to be effective in the prevention of post-operative recurrence, but some 50% of patients under treatment recur at 3 years of follow-up. AIM:To establish whether the mucosal conce...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00501.x

    authors: Frieri G,Pimpo MT,Andreoli A,Annese V,Comberlato M,Corrao G,Palumbo G,Sturniolo GC,Tonelli F,Caprilli R

    更新日期:1999-05-01 00:00:00

  • Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?

    abstract::Summary In patients with gastro-oesophageal reflux disease, the pH of refluxed gastric contents has a direct bearing on disease severity and oesophageal damage. A pH of 4 has been defined as a threshold below which refluxed gastric contents become injurious to the oesophagus. Studies in patients with erosive oesophagi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02140.x

    authors: Armstrong D

    更新日期:2004-10-01 00:00:00

  • Identifying responders to acid suppression in dyspepsia using a random starting day trial.

    abstract:BACKGROUND:Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely. This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2000.00866.x

    authors: Bytzer P,Hansen JM,Rune S,Bonnevie O,Breinstrup H,Funch-Jensen P,Matzen P,Meineche-Schmidt V,Schaffalitzky De Muckadell OB

    更新日期:2000-11-01 00:00:00

  • The effect of portal hypertension on indomethacin-induced small intestinal ulceration in the rat.

    abstract::The purpose of this study was to determine whether portal hypertension potentiates intestinal ulceration induced by indomethacin. Portal hypertension was produced in male Sprague-Dawley rats by two-staged ligation of the portal vein. Sham-operated rats were used as controls. The rats were given 20 mg/kg of indomethaci...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1991.tb00004.x

    authors: Jonas GM,Erickson RA,Chung K

    更新日期:1991-02-01 00:00:00